Home › Free Stock Grades › MYGN
Myriad Genetics, Inc. (MYGN) Stock Grade
MYGN · Healthcare
C
Market Cap
$573.8M
P/E Ratio
—
Revenue Growth (YoY)
-1.6%
Net Margin
-44.4%
Return on Equity
—
Dividend Yield
None
About Myriad Genetics, Inc.'s fundamentals
Myriad Genetics is a medical diagnostics and research company with a market capitalization of $573.8 million that reported revenue decline of 1.6% year-over-year in its latest period. The company operates at a significant loss, with a net margin of -44.4%, reflecting that expenses substantially exceed revenues. Myriad does not pay a dividend and reported a net loss in its latest annual statement, indicating the company is not yet profitable despite its established position in the diagnostics sector.